News

(Reuters) - Europe's leading association of oncologists has thrown its weight behind cheaper copycat versions of biotech cancer drugs that have lost patent protection, saying they are effective and affordable. Off-patent chemical medicines have for decades been copied with precision and sold as cheap generic versions, but drug regulators have only over recent years embraced copycat versions of complex biological drugs, known as biosimilars. "Biosimilars are must-have weaponry in financially sustaining healthcare systems on a global scale as well as significantly improving outcomes for an increasing number of patients throughout Europe and the rest of the world," ESMO President Professor Fortunato Ciardiello said in a statement.


Science News Headlines - Yahoo News

Science News Headlines - Yahoo News

Get the latest Science news headlines from Yahoo News. Find breaking Science news, including analysis and opinion on top Science stories.

Published: Fri, 20 Jan 2017 09:42:50 -0500
Copyright: Copyright (c) 2017 Yahoo! Inc. All rights reserved